Loading data for BLTE — first visit, this takes a few seconds.

アラート

Belite Bio Inc (BLTE)

NasdaqCM: BLTE · リアルタイム株価 · USD

156.69

-4.99 (-3.09%)

終値時点： Aug 27, 2026, 8:00 PM

160.00

+1.90%

時間外: 4:40 PM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

-3.09% (1D)

データがありません

買気配	115.43
時価総額	6.32B
売上高（TTM）	n/a
純利益（TTM）	-102.36M
	-1.23
	-2.74
	n/a
	73.32
PBR（TTM）	8.14
PSR（TTM）	n/a
決算発表日	Nov 9, 2026

売気配	200.11
出来高	263,953
平均出来高（20日）	208,198
始値	162.44
前日終値	161.68
当日レンジ	155.32 - 162.44
52週レンジ	62.18 - 200.00
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

BLTEについて

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The c...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Apr 29, 2022

従業員数 41

上場取引所 NasdaqCM

ティッカー BLTE

ウェブサイト https://www.belitebio.com

企業情報の全文

業績

2025年のBelite Bio Incの売上高は0で、前年の0からundefined%の増加でした。利益は-77.61Mで、114.73%の増加でした。

財務諸表

決算サプライズ

Belite Bio IncはAug 13, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.
EPSは -0.7 で、予想を上回りました 0.08, うち -40.00% の前年比減少.

次回決算発表

Belite Bio Incの決算発表予定日は Nov 9, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード

ニュース

2週間前 · Simply Wall St.

Belite Bio (BLTE) Could Be 21% Undervalued On FDA Priority Review News

Belite Bio (BLTE) is back in focus after the FDA accepted its New Drug Application for tinlarebant with Priority Review, a key regulatory step that accompanies the company’s latest quarterly earnings ...

2週間前 · Simply Wall St.

Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run

Belite Bio stock has delivered a very large 431.2% return over the past three years, while its valuation checks and current market multiples point to a less straightforward picture of how much is alre...

2週間前 · GuruFocus.com

Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ...

Belite Bio Inc (BLTE) reports robust progress with FDA NDA acceptance and a $780 million cash runway, despite widening losses and delayed GA trial interim analysis.

2週間前 · MarketBeat

Belite Bio Q2 Earnings Call Highlights

Belite Bio (NASDAQ:BLTE) said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the applicati...

2週間前 · Zacks

BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.

2ページ中1ページ

Belite Bio Inc (BLTE)